文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis.

作者信息

Richardson Tim, Schütte Daniel, Kobbe Guido, Baermann Ben-Niklas, Holderried Tobias A W, Schmitz Friederike, Crysandt Martina, Hallek Michael, Scheid Christoph, Holtick Udo, Cornely Oliver A, Stemler Jannik, Mellinghoff Sibylle C

机构信息

Department I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Institute for Computational Cancer Biology Cologne, Cologne, Germany.

出版信息

Blood Adv. 2025 Mar 25;9(6):1370-1375. doi: 10.1182/bloodadvances.2024015008.

DOI:10.1182/bloodadvances.2024015008
PMID:39746178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11957513/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b41f/11957513/8bde1014c00a/BLOODA_ADV-2024-015008-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b41f/11957513/8bde1014c00a/BLOODA_ADV-2024-015008-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b41f/11957513/8bde1014c00a/BLOODA_ADV-2024-015008-gr1.jpg

相似文献

[1]
Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis.

Blood Adv. 2025-3-25

[2]
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.

Blood. 2023-2-16

[3]
Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.

Blood Adv. 2024-5-14

[4]
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.

Lancet Haematol. 2025-5

[5]
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy.

Front Immunol. 2024

[6]
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.

J Nanobiotechnology. 2024-5-23

[7]
BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma.

Clin Lymphoma Myeloma Leuk. 2025-1

[8]
Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.

Transplant Cell Ther. 2021-6

[9]
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.

Adv Ther. 2024-8

[10]
Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.

Mol Ther. 2025-7-2

引用本文的文献

[1]
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.

Blood Cancer J. 2025-7-2

[2]
Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy.

Blood Adv. 2025-8-26

本文引用的文献

[1]
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.

Nat Med. 2024-9

[2]
The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention.

Open Forum Infect Dis. 2024-3-13

[3]
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.

Blood Cancer J. 2024-5-31

[4]
Vaccination of Adults With Cancer: ASCO Guideline.

J Clin Oncol. 2024-5-10

[5]
Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies.

Transpl Infect Dis. 2023-11

[6]
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

Nat Med. 2023-9

[7]
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.

Blood Cancer J. 2023-8-1

[8]
Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.

Transpl Infect Dis. 2023-11

[9]
Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy.

Blood Adv. 2023-9-26

[10]
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.

Lancet Oncol. 2023-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索